Cargando…

Relationship between the agonist activity of synthetic ligands of TRAIL-R2 and their cell surface binding modes

Tumor Necrosis Factor Receptor Apoptosis Inducing Ligand (TRAIL) appears as an interesting candidate for targeted cancer therapy as it induces apoptosis in cancer cells without toxicity to normal cells. TRAIL elicits apoptosis through agonist death receptor TRAIL-R1 and TRAIL-R2 engagement. Neverthe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chekkat, Neila, Lombardo, Caterina M., Seguin, Cendrine, Lechner, Marie-Charlotte, Dufour, Florent, Nominé, Yves, De Giorgi, Marcella, Frisch, Benoit, Micheau, Olivier, Guichard, Gilles, Altschuh, Danièle, Fournel, Sylvie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884648/ https://www.ncbi.nlm.nih.gov/pubmed/29643993 http://dx.doi.org/10.18632/oncotarget.24526

Ejemplares similares

Synthetic ligands of death receptor 5 display a cell-selective agonistic effect at different oligomerization levels
por: Beyrath, Julien, et al.
Publicado: (2016)

Hetero-oligomerization between the TNF receptor superfamily members CD40, Fas and TRAILR2 modulate CD40 signalling
por: Smulski, Cristian R, et al.
Publicado: (2017)

N-Heterocyclic Carbene-Polyethyleneimine (PEI) Platinum Complexes Inducing Human Cancer Cell Death: Polymer Carrier Impact
por: Wantz, May, et al.
Publicado: (2018)

TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress
por: Dufour, Florent, et al.
Publicado: (2016)

N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death
por: Dufour, Florent, et al.
Publicado: (2017)

Antibody Binding Selectivity: Alternative Sets of Antigen Residues Entail High-Affinity Recognition
por: Nominé, Yves, et al.
Publicado: (2015)

Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy
por: Elmallah, Mohammed I. Y., et al.
Publicado: (2019)

Regulating TRAIL Receptor-Induced Cell Death at the Membrane: A Deadly Discussion
por: Shirley, Sarah, et al.
Publicado: (2011)

Marine Drugs Regulating Apoptosis Induced by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)
por: Elmallah, Mohammed I. Y., et al.
Publicado: (2015)

Grafting TRAIL through Either Amino or Carboxylic Groups onto Maghemite Nanoparticles: Influence on Pro-Apoptotic Efficiency
por: Belkahla, Hanene, et al.
Publicado: (2021)

Performance of Pyridylthiourea‐Polyethylenimine Polyplex for siRNA‐Mediated Liver Cancer Therapy in Cell Monolayer, Spheroid, and Tumor Xenograft Models
por: Gossart, Jean Baptiste, et al.
Publicado: (2017)

TRAIL acts synergistically with iron oxide nanocluster-mediated magneto- and photothermia
por: Belkahla, Hanene, et al.
Publicado: (2019)

Low-Level Endothelial TRAIL-Receptor Expression Obstructs the CNS-Delivery of Angiopep-2 Functionalised TRAIL-Receptor Agonists for the Treatment of Glioblastoma
por: Krishna Moorthy, Nivetha, et al.
Publicado: (2021)

Molecular Mode of Action of TRAIL Receptor Agonists—Common Principles and Their Translational Exploitation
por: Wajant, Harald
Publicado: (2019)

Marine Actinomycetes-Derived Secondary Metabolites Overcome TRAIL-Resistance via the Intrinsic Pathway through Downregulation of Survivin and XIAP
por: Elmallah, Mohammed I. Y., et al.
Publicado: (2020)

TRAIL Triggers CRAC-Dependent Calcium Influx and Apoptosis through the Recruitment of Autophagy Proteins to Death-Inducing Signaling Complex
por: Airiau, Kelly, et al.
Publicado: (2021)

TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2
por: Tamada, Taro, et al.
Publicado: (2015)

Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists
por: Urso, Loredana, et al.
Publicado: (2017)

Toll-Like Receptor Agonists Synergize with CD40L to Induce Either Proliferation or Plasma Cell Differentiation of Mouse B Cells
por: Boeglin, Emmanuelle, et al.
Publicado: (2011)

Dacarbazine and the Agonistic TRAIL Receptor-2 Antibody Lexatumumab Induce Synergistic Anticancer Effects in Melanoma
por: Engesæter, Birgit, et al.
Publicado: (2012)

Identification of Novel Epitopes with Agonistic Activity for the Development of Tumor Immunotherapy Targeting TRAIL-R1
por: Guo, Lu, et al.
Publicado: (2017)

Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells
por: Trivedi, Rachana, et al.
Publicado: (2015)

TRAIL-R4 Promotes Tumor Growth and Resistance to Apoptosis in Cervical Carcinoma HeLa Cells through AKT
por: Lalaoui, Najoua, et al.
Publicado: (2011)

tert-Butyl 3-oxo-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxylate
por: Lechner, Marie-Charlotte, et al.
Publicado: (2008)

hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma
por: Fleten, Karianne G, et al.
Publicado: (2016)

The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells
por: Legler, Karen, et al.
Publicado: (2018)

Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist
por: Boccellato, Chiara, et al.
Publicado: (2021)

Therapeutic Effects of Synthetic Antimicrobial Peptides, TRAIL and NRP1 Blocking Peptides in Psoriatic Keratinocytes
por: Ryu, Sunhyo, et al.
Publicado: (2019)

Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis
por: Abdulghani, Junaid, et al.
Publicado: (2013)

Computational design of a synthetic PD-1 agonist
por: Bryan, Cassie M., et al.
Publicado: (2021)

ProFeatMap: a highly customizable tool for 2D feature representation of protein sets
por: Bich, Goran, et al.
Publicado: (2023)

Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin
por: Belyanskaya, Larisa L, et al.
Publicado: (2007)

TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic
por: Ralff, Marie D., et al.
Publicado: (2020)

Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists
por: Grinkevitch, Vera, et al.
Publicado: (2022)

TRAIL/TRAIL Receptor System and Susceptibility to Multiple Sclerosis
por: López-Gómez, Carlos, et al.
Publicado: (2011)

TRAIL combinations: The new ‘trail’ for cancer therapy (Review)
por: REFAAT, ALAA, et al.
Publicado: (2014)

Synthetic Flavanones Augment the Anticancer Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)
por: Szliszka, Ewelina, et al.
Publicado: (2012)

Design of Oligourea-Based Foldamers with Antibacterial and Antifungal Activities
por: Tallet, Lorène, et al.
Publicado: (2022)

Regulation of Circadian Behavior and Metabolism by Synthetic REV-ERB Agonists
por: Solt, Laura A., et al.
Publicado: (2012)

Computational Study of Synthetic Agonist Ligands of Ionotropic Glutamate Receptors
por: Wolter, Tino, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ock12fpu3apojo8858f8536iu3